Clinical trial · Observational
Assessment of Eloquent Function in Brain Tumor Patients
Assessment of Reorganization and Plasticity of Eloquent Function in Patients With Brain Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose of the study: AIM 1: Prospectively collect pre-operative \[functional magnetic resonance imaging (fMRI), diffusion tensor imaging (DTI), magnetoencephalography (MEG)\] and intra-operative mapping data in patients with intra-axial brain tumors to assess how well each modality predicts the location of eloquent brain function. In addition, each modality will be compared with the other. AIM 2: Assess reorganization of eloquent brain function and plasticity in patients with intra-axial brain tumors. This will be accomplished by prospectively collecting post-operative mapping studies and neuropsychological tests to compare them to prior mapping studies as stated above.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Brain Tumor | Brain Neoplasm | CURATED_BROADER | 0.78 |
| Primary Brain Tumor | Primary Brain Tumor | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brain mapping | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Eloquent area tumor
- description
- Standard of care with brain mapping, pre-, intra-, and post-operative.
- interventionNames
- Diagnostic Test: Brain mapping
Primary outcomes (1)
- measure
- Eloquent function
- timeFrame
- 1 year
- description
- The location of the eloquent function of interest (motor, sensory, speech) will be assessed pre-operatively and intra-operatively and compared. Then, at 2 and 6 months post-operatively, repeat non-invasive mapping studies will be performed to compare to the subjects' prior studies. This will allow for assessment of reorganization and plasticity of function. Additionally, novel ways of identifying eloquent brain regions will be developed.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * 19 years and older * Brain tumor in or near eloquent brain regions that is appropriate for attempted resection * Appropriate body habitus and mental status/capacity to participate with non-invasive or invasive mapping * Benign or malignant intra-axial brain tumor * Primary or metastatic intra-axial brain tumor Exclusion Criteria: * Any contraindication to MRI (i.e. implanted devices) * Inappropriate body habitus or mental status/capacity to participate with non-invasive or invasive mapping in a safe and reliable manner * Declining to participate * Lacks capacity to understand the study or consent for themselves * Neurologic status which precludes testing (poor function- not testable) * Positive pregnancy test * End stage renal disease or severe renal dysfunction
References
Publications (1)
- DERIVEDEllis DG, White ML, Hayasaka S, Warren DE, Wilson TW, Aizenberg MR. Accuracy analysis of fMRI and MEG activations determined by intraoperative mapping. Neurosurg Focus. 2020 Feb 1;48(2):E13. doi: 10.3171/2019.11.FOCUS19784. PMID 32006951